重组人组织纤溶酶原激酶衍生物溶栓治疗心肌梗塞的疗效

王艾1 ，刘军荣2

（陕西省泾阳县医院：1.心血管内科；2. 神经外科，陕西 咸阳，713700）

浏览次数：67次 下载次数：335次

摘要：

目的 研究重组人组织纤溶酶原激酶衍生物溶栓治疗心肌梗塞的效果。方法 回顾性分析我院收治的100 例急性心肌 梗塞患者的临床资料，依照其入院顺序分为研究组和对照组，各50 例。研究组接受重组人组织纤溶酶原激酶衍生物溶栓治 疗，对照组接受尿激酶溶栓治疗。比较两组患者的血管开通率、死亡率，血液流变学指标改变情况和不良反应发生情况。结果 溶栓治疗后，研究组血管开通率明显高于对照组，差异显著（P<0.05）；研究组患者死亡率（0.0%）明显低于对照组 （6.0%）（P<0.05）；研究组患者的红细胞刚性指数、全血粘度及红细胞聚集指数明显低于对照组，差异显著（P<0.05）；研究组 患者不良反应发生率明显低于对照组（P<0.05）。结论 给予心肌梗塞患者重组人组织纤溶酶原激酶衍生物溶栓治疗，可以显 著提升血管开通率，改善患者的血液流变学各指标水平，治疗效果显著，安全性高，值得临床推广。

关键词：心肌梗塞；重组人组织纤溶酶原激酶衍生物；溶栓治疗

中图分类号：R542.22文献标志码：A文章编号：2096-1413(2017)35-0024-02

Effect of recombinant human tissue plasminogen kinase derivative for thrombolytic therapy in myocardial infarction
WANG Ai 1, LIU Jun-rong 2
(1. Cardiovascular Department; 2. Neurosurgery Department, Jingyang County Hospital, Xianyang 713700, China)

ABSTRACT: Objective To study the effect of recombinant human tissue plasminogen kinase derivative for thrombolytic therapy in myocardial infarction. Methods The clinical data of 100 acute myocardial infarction patients were analyzed retrospectively, and all the patients divided into study group and control group according to the order of admission, with 50 cases in each group. The study group received recombinant human tissue plasminogen kinase derivative for thrombolytic therapy, the control group received urokinase for thrombolytic therapy. The patency rate, mortality, the changes of blood rheology and the occurrence of adverse reactions were compared. Results After thrombolytic therapy, the patency rate in the study group was significantly higher than that in the control group (P<0.05); the mortality of patients in the study group (0.0%) was significantly lower than the control group (6.0%) (P<0.05); the red cell rigidity index, whole blood viscosity and red cell aggregation index in the study group were significantly lower than those in the control group (P<0.05); the incidence of adverse reactions in the study group was significantly lower than that in the control group (P<0.05). Conclusion Recombinant human tissue plasminogen kinase derivative for thrombolytic therapy in myocardial infarction can significantly improve the patency rate and patients`` blood rheology, with significant curative effect and high safety, which is worthy of promotion.
KEYWORDS: myocardial infarction; recombinant human tissue plasminogen kinase derivative; thrombolytic therapy

参考文献：
[1] 马骏,徐琳,李叶阔,等.急性心肌梗死恢复期V1 导联P 波终末电 势与左室舒张功能的相关性研究[J].中国现代医学杂志,2012,32(17):3789-3790.
[2] 玛力亚·哈布力,木拉里·黑亚孜.老年糖尿病合并急性心肌梗死患 者糖化血红蛋白与肌酸激酶及其同工酶的相关性研究[J].临床医药 文献电子杂志,2013,19(10):892-893.
[3] 罗洪强,钟永根,周国忠,等.Th1/Th2 细胞平衡偏移在原发性免疫 性血小板减少性紫癜发病机制中的作用[J].中国卫生检验杂志,2014,6(28):17-19.
[4] 邹秀英.重组人组织型纤溶酶原激酶衍生物对于急性心肌梗死多 项血清白介素、热休克蛋白70 及血液流变学的影响研究[J].中国当代医药,2014,18(26):14-16.
[5] GEYIK B,OZDEMIR O,OSMONOV D,et al.N -terminal pro -brain natriuretic peptide and electrocardiographic variables associated with increased risk of complete atrioventricular block and mortality in patients with acute inferior myocardial infarction[J].Cardiol J,2012,19(5): 479-486.
[6] GHANAVATIAN S,STEIN RA,ATAR D,et al.The course of D-dimer high-sensitivity C-reactive protein and pro-B-type natriuretic peptide in patients with non -ST -elevation myocardial infarction [J].Clin Lab, 2011,57(9):771-776.